PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 9:20 AM ET

Sponsor Check › Person

SH
No photo found yet (own website and image search run after this page is viewed)

Seth Harrison

Named as an officer, director or promoter on SEC Form D filings · MA, NY, CA · Apr 10, 2009 → Feb 28, 2022

22deals (issuers)
$522.7Mreported sold
156investors
49Form D filings
2009–2022years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:18 AM ET · SEC enforcement last checked: Oct 24, 2026, 1:50 AM ET

The short version

Seth Harrison is listed as an executive officer and director on 49 SEC Form D filings by 22 issuers between Apr 2009 and Sep 2025. Largest by amount reported sold: Eledon Pharmaceuticals, Inc. (Irvine, CA — biotechnology — 2009–2013; $108.1M reported sold to 38 investors), Galvanize Therapeutics, Inc. (Redwood City, CA — biotechnology — 2019–2025; $96.1M reported sold to 28 investors), Stoke Therapeutics, Inc. (Bedford, MA — biotechnology — 2018; $90M reported sold to 14 investors), HeartWare International, Inc. (Framingham, MA — other health care — 2009; $55M reported sold to 30 investors), AILERON THERAPEUTICS INC (Waltham, MA — biotechnology — 2009–2017; $30.1M reported sold to 15 investors) and 17 more (all listed below).

What this means That is a lot of deals — 22 separate companies raised money with this person listed as executive officer and director, over about 16 years. Across those companies the filings report $522.7M sold in total.

Listed alongside Jonathan Waldstreicher (11 shared filings), Joseph A. Yanchik III (10 shared filings), Michael Ehlers (8 shared filings), Spiros Liras (8 shared filings), Aaron Kantoff (6 shared filings) and 79 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Seth. Each name links to their own page.

3 of the issuers belong to the sponsor group Galvanize Therapeutics (3 issuers, $103M reported sold, 2019–2025).

What this means A sponsor group is one team that sets up a new company for each deal. Galvanize Therapeutics has 3 companies on file and $103M reported sold in total — the group page shows the whole track record in one place.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — 4 bankruptcy cases matching the name listed in Key records below.

What this means 4 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared 49 public filings for Seth Harrison and found 14 differences, 6 worth asking the sponsor about: Amount sold went down between filings; Investor count went down between filings; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Seth Harrison has not run yet — it is joining a line of 31,044 names; searches run around the clock at the hosts' allowed rate. Searched so far: 638 names.

Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:18 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (checked Oct 24, 2026) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET

What was searched

SEC enforcement searched: SEC litigation releases + SEC administrative proceedings (sec.gov index, 1995-09-19 → 2026-10-23) — last checked Oct 24, 2026, 1:50 AM ET.

State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).

3. Bankruptcies

4 cases: 1 open, 3 closed (disposition not in docket feed)

Seth P Harrison open
United States Bankruptcy Court, E.D. Virginia · No. 24-31373 · Filed Apr 11, 2024
Role of Seth P Harrison: Debtor · Outcome: Open — no termination date on the docket (bulk snapshot 2026-09-30) Docket on CourtListener ↗
same full name (a name found in 6 federal dockets); 3 people with this name in Form D filings; court in VA (not a filing state)
Seth P. Harrison closed
United States Bankruptcy Court, E.D. Virginia · No. 17-35369 · Filed Oct 26, 2017 · Closed Feb 26, 2018
Role of Seth P. Harrison: Debtor · Outcome: Case closed 2018-02-26 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 6 federal dockets); 3 people with this name in Form D filings; court in VA (not a filing state)
Seth Harrison and Carole Ann Harrison closed
United States Bankruptcy Court, E.D. Pennsylvania · No. 10-30146 · Filed Nov 22, 2010 · Closed Aug 18, 2014
Role of Seth Harrison and Carole Ann Harrison: Debtor · Outcome: Case closed 2014-08-18 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 6 federal dockets); 3 people with this name in Form D filings; court in PA (not a filing state)
Seth Harrison closed
United States Bankruptcy Court, E.D. Pennsylvania · No. 06-12840 · Filed Jul 10, 2006 · Closed Oct 16, 2006
Role of Seth Harrison: Debtor · Outcome: Case closed 2006-10-16 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 6 federal dockets); 3 people with this name in Form D filings; court in PA (not a filing state)
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:18 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

14 differences found between the filings for Seth Harrison — 6 worth asking about (compared 49 filings on Oct 24, 2026)

Worth asking · Aug 14, 2009 – Oct 5, 2009

Amount sold went down between filings — HeartWare International, Inc.

The Aug 14, 2009 filing says $55,000,000 sold; the Oct 5, 2009 Form D says $220,000 sold — $54,780,000 less.

What this means Amounts sold normally only go up as a raise continues. A drop can mean investors were refunded, a figure was corrected, or an earlier number was wrong. Ask the sponsor which it was.

Form D (earlier) · Aug 14, 2009 ↗Form D (later) · Oct 5, 2009 ↗HeartWare International, Inc. — PartnerFacts page ↗
Sources
Worth asking · Jun 10, 2009 – Jul 17, 2009

Amount sold went down between filings — Gloucester Pharmaceuticals Inc

The Jun 10, 2009 filing says $1,500,000 sold; the Jul 17, 2009 Form D says $500,000 sold — $1,000,000 less.

What this means Amounts sold normally only go up as a raise continues. A drop can mean investors were refunded, a figure was corrected, or an earlier number was wrong. Ask the sponsor which it was.

Form D (earlier) · Jun 10, 2009 ↗Form D (later) · Jul 17, 2009 ↗Gloucester Pharmaceuticals Inc — PartnerFacts page ↗
Sources
Worth asking · May 6, 2009 – Jun 10, 2009

Amount sold went down between filings — Gloucester Pharmaceuticals Inc

The May 6, 2009 filing says $1,700,000 sold; the Jun 10, 2009 Form D says $1,500,000 sold — $200,000 less.

What this means Amounts sold normally only go up as a raise continues. A drop can mean investors were refunded, a figure was corrected, or an earlier number was wrong. Ask the sponsor which it was.

Form D (earlier) · May 6, 2009 ↗Form D (later) · Jun 10, 2009 ↗Gloucester Pharmaceuticals Inc — PartnerFacts page ↗
Sources
Worth asking · Aug 14, 2009 – Oct 5, 2009

Investor count went down between filings — HeartWare International, Inc.

The Aug 14, 2009 filing reports 30 investors; the Oct 5, 2009 Form D reports 1 investor.

What this means Investor counts normally only grow. A smaller number can mean investors left or were refunded, or a count was corrected. Ask the sponsor what happened.

Form D (earlier) · Aug 14, 2009 ↗Form D (later) · Oct 5, 2009 ↗HeartWare International, Inc. — PartnerFacts page ↗
Sources
Worth asking · May 18, 2017 – Aug 10, 2023

Seth Harrison appears on 14 deals that stopped filing before reaching their target

Aulos Bioscience, Inc. (last filing Aug 10, 2023; $15,000,000 sold of $40,000,000); Aethon Therapeutics, Inc. (last filing Dec 22, 2022; $6,000,000 sold of $30,000,000); Replicate Bioscience, Inc. (last filing Mar 9, 2022; $20,000,000 sold of $53,000,000); Marlinspike Therapeutics, Inc. (last filing Feb 28, 2022; $3,500,000 sold of $65,000,000); Deep Apple Therapeutics, Inc. (last filing Dec 22, 2021; $5,000,000 sold of $52,000,000); Galaxy Medical, Inc. (last filing Nov 10, 2021; $8,000,000 sold of $18,000,000); and 8 more. Each has no filing in more than two years and reported under half its target sold.

What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.

Aulos Bioscience, Inc. — PartnerFacts page ↗Aethon Therapeutics, Inc. — PartnerFacts page ↗Replicate Bioscience, Inc. — PartnerFacts page ↗Marlinspike Therapeutics, Inc. — PartnerFacts page ↗
Sources
Worth asking · Oct 24, 2014 – Sep 11, 2025

5 Form Ds were filed more than 15 days after the first sale

Form D filed 66 days after the first sale — Galvanize Therapeutics, Inc. · Form D filed 26 days after the first sale — Marlinspike Therapeutics, Inc. · Form D filed 16 days after the first sale — Deep Apple Therapeutics, Inc. · Form D filed 20 days after the first sale — Red Queen Therapeutics, Inc. · Form D filed 21 days after the first sale — Cure Forward Corp.

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Sep 11, 2025 ↗Galvanize Therapeutics, Inc. — PartnerFacts page ↗Form D · Feb 28, 2022 ↗Marlinspike Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Mar 30, 2009 – Sep 11, 2025

26 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — Galvanize Therapeutics, Inc. (latest filing Sep 11, 2025) · No amendment in the last 12 months on an offering that may still be open — Aulos Bioscience, Inc. (latest filing Aug 10, 2023) · No amendment in the last 12 months on an offering that may still be open — Aethon Therapeutics, Inc. (latest filing Dec 22, 2022) · No amendment in the last 12 months on an offering that may still be open — Replicate Bioscience, Inc. (latest filing Mar 9, 2022) · No amendment in the last 12 months on an offering that may still be open — Marlinspike Therapeutics, Inc. (latest filing Feb 28, 2022) · and 21 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Sep 11, 2025 ↗Galvanize Therapeutics, Inc. — PartnerFacts page ↗Form D · Aug 10, 2023 ↗Aulos Bioscience, Inc. — PartnerFacts page ↗
Sources
Note · Sep 20, 2011 – May 15, 2013

Seth Harrison's role changed at Eledon Pharmaceuticals, Inc.: executive officer, director → director

The Sep 20, 2011 filing lists Seth Harrison as executive officer, director; the May 15, 2013 Form D lists director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D · Sep 20, 2011 ↗Form D · May 15, 2013 ↗Seth Harrison — PartnerFacts page ↗Eledon Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Apr 10, 2009 – Mar 9, 2022

11 offerings changed their target amount between filings

Offering amount changed between filings — Replicate Bioscience, Inc. · Offering amount changed between filings — Galvanize Therapeutics, Inc. · Offering amount changed between filings — Galaxy Medical, Inc. · Offering amount changed between filings — Galvanize Therapeutics, Inc. · Offering amount changed between filings — Cure Forward Corp. · and 6 more

What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.

Form D (earlier) · Feb 16, 2021 ↗Form D/A (later) · Mar 9, 2022 ↗Replicate Bioscience, Inc. — PartnerFacts page ↗Form D (earlier) · Apr 1, 2020 ↗
Sources
Note · Apr 10, 2009 – May 6, 2009

Seth Harrison is written 2 different ways on the filings

listed as "Seth Harrison" on 42 filings (from Apr 10, 2009), and "Seth L. Harrison" on 7 filings (from May 6, 2009).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Apr 10, 2009 ↗Form D · May 6, 2009 ↗Seth Harrison — PartnerFacts page ↗
Sources
Note · Aug 15, 2019

Same name, different state: "Seth L. Harrison" (PA) is a separate record

This page covers filings where the address state is MA or NY or CA. A separate record, "Seth L. Harrison" with address state PA, is listed on 1 filing — most recently by Limelight Bio, Inc. (Aug 15, 2019). Both records have filings in the same period (Aug 15, 2019).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Seth L. Harrison (PA) — PartnerFacts page ↗Form D · Aug 15, 2019 ↗Limelight Bio, Inc. — PartnerFacts page ↗Seth Harrison (MA,NY,CA) — this page ↗
Sources
Note · Jun 28, 2012

Same name, different state: "Seth L. Harrison" (NY or NJ) is a separate record

This page covers filings where the address state is MA or NY or CA. A separate record, "Seth L. Harrison" with address state NY or NJ, is listed on 2 filings — most recently by Apple Tree Partners II - Annex, L.P. (Nov 4, 2013). Both records have filings in the same period (Jun 28, 2012).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Seth L. Harrison (NY,NJ) — PartnerFacts page ↗Form D · Nov 4, 2013 ↗Apple Tree Partners II - Annex, L.P. — PartnerFacts page ↗Seth Harrison (MA,NY,CA) — this page ↗
Sources
Note · Sep 29, 2016 – Sep 11, 2025

4 address changes between filings

Address moved from San Carlos, CA to Redwood City, CA — Galvanize Therapeutics, Inc. · Address moved from Menlo Park, CA to San Carlos, CA — Galvanize Therapeutics, Inc. · Address moved from Menlo Park, CA to San Carlos, CA — Galaxy Medical, Inc. · Address moved from Cambridge, MA to Boston, MA — Cure Forward Corp.

What this means Businesses move. If you were told one city and the forms say another, ask which is current.

Form D · Mar 22, 2022 ↗Form D · Sep 11, 2025 ↗Galvanize Therapeutics, Inc. — PartnerFacts page ↗Form D/A · Nov 18, 2019 ↗
Sources
Note · Apr 10, 2009 – Sep 11, 2025

Seth Harrison is listed with 3 different address states: MA, NY, CA

MA on 24 filings (Apr 10, 2009 to Feb 28, 2022); NY on 9 filings (Oct 24, 2014 to Dec 22, 2022); CA on 16 filings (Jul 11, 2019 to Sep 11, 2025).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D · Apr 10, 2009 ↗Form D · Oct 24, 2014 ↗Form D · Jul 11, 2019 ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

0 of 36 offerings report sales commissions; 0 report finder's fees; 0 report proceeds to related persons.

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Sep 11, 2025 D
Galvanize Therapeutics, Inc.
File 021-557260
$0$0$0None listed on this filingEDGAR ↗
Aug 10, 2023 D
Aulos Bioscience, Inc.
File 021-489397
$0$0$0None listed on this filingEDGAR ↗
Dec 22, 2022 D
Aethon Therapeutics, Inc.
File 021-468421
$0$0$0None listed on this filingEDGAR ↗
Mar 22, 2022 D
Galvanize Therapeutics, Inc.
File 021-438335
$0$0$0None listed on this filingEDGAR ↗
Mar 9, 2022 D/A
Replicate Bioscience, Inc.
File 021-389517
$0$0$0None listed on this filingEDGAR ↗
Mar 9, 2022 D
Galvanize Therapeutics, Inc.
File 021-436586
$0$0$0None listed on this filingEDGAR ↗
Feb 28, 2022 D
Marlinspike Therapeutics, Inc.
File 021-435285
$0$0$0None listed on this filingEDGAR ↗
Dec 22, 2021 D
Deep Apple Therapeutics, Inc.
File 021-426368
$0$0$0None listed on this filingEDGAR ↗
Nov 10, 2021 D
Galaxy Medical, Inc.
File 021-420659
$0$0$0None listed on this filingEDGAR ↗
Nov 2, 2021 D
Red Queen Therapeutics, Inc.
File 021-419494
$0$0$0None listed on this filingEDGAR ↗
Oct 4, 2021 D
Galaxy Medical, Inc.
File 021-415544
$0$0$0None listed on this filingEDGAR ↗
Aug 25, 2021 D
Evercrisp Biosciences, Inc.
File 021-411281
$0$0$0None listed on this filingEDGAR ↗
Feb 4, 2021 D/A
Initial Therapeutics, Inc.
File 021-371190
$0$0$0None listed on this filingEDGAR ↗
Feb 3, 2021 D/A
Nine Square Therapeutics Corp
File 021-370079
$0$0$0None listed on this filingEDGAR ↗
Nov 17, 2020 D
Apertor Pharmaceuticals, Inc.
File 021-380841
$0$0$0None listed on this filingEDGAR ↗
Oct 29, 2020 D/A
Galaxy Medical, Inc.
File 021-364146
$0$0$0None listed on this filingEDGAR ↗
Oct 29, 2020 D/A
Galvanize Therapeutics, Inc.
File 021-364148
$0$0$0None listed on this filingEDGAR ↗
Apr 1, 2020 D
Galavant Therapeutics, Inc.
File 021-364151
$0$0$0None listed on this filingEDGAR ↗
Nov 18, 2019 D/A
Galvanize Therapeutics, Inc.
File 021-334782
$0$0$0None listed on this filingEDGAR ↗
Oct 15, 2019 D
Tusker Medical, Inc.
File 021-351035
$0$0$0None listed on this filingEDGAR ↗
Jul 11, 2019 D
Tusker Medical, Inc.
File 021-344057
$0$0$0None listed on this filingEDGAR ↗
Nov 2, 2018 D
Stoke Therapeutics, Inc.
File 021-324958
$0$0$0None listed on this filingEDGAR ↗
May 18, 2017 D/A
Cure Forward Corp.
File 021-276663
$0$0$0None listed on this filingEDGAR ↗
Jan 6, 2017 D
AILERON THERAPEUTICS INC
File 021-277814
$0$0$0None listed on this filingEDGAR ↗
Sep 29, 2016 D
Cure Forward Corp.
File 021-271499
$0$0$0None listed on this filingEDGAR ↗
Jun 22, 2015 D/A
Cure Forward Corp.
File 021-228382
$0$0$0None listed on this filingEDGAR ↗
Jun 22, 2015 D
Cure Forward Corp.
File 021-242208
$0$0$0None listed on this filingEDGAR ↗
Oct 29, 2014 D
AILERON THERAPEUTICS INC
File 021-227346
$0$0$0None listed on this filingEDGAR ↗
Oct 24, 2014 D
Syntimmune, Inc.
File 021-227085
$0$0$0None listed on this filingEDGAR ↗
Nov 19, 2013 D
AILERON THERAPEUTICS INC
File 021-206573
$0$0$0None listed on this filingEDGAR ↗
May 15, 2013 D
Eledon Pharmaceuticals, Inc.
File 021-196513
$0$0$0None listed on this filingEDGAR ↗
Sep 20, 2011 D
Eledon Pharmaceuticals, Inc.
File 021-166079
$0$0$0None listed on this filingEDGAR ↗
Oct 5, 2009 D
HeartWare International, Inc.
File 021-107336
$0$0$0None listed on this filingEDGAR ↗
Aug 21, 2009 D
Gloucester Pharmaceuticals Inc
File 021-70770
$0$0$0None listed on this filingEDGAR ↗
Jun 12, 2009 D
AILERON THERAPEUTICS INC
File 021-111808
$0$0$0None listed on this filingEDGAR ↗
May 6, 2009 D
Eledon Pharmaceuticals, Inc.
File 021-104904
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 22

Every issuer that named Seth Harrison on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

GT
Biotechnology · group: Galvanize Therapeutics

Galvanize Therapeutics, Inc.

Redwood City, CA · Nov 18, 2019 → Sep 11, 2025 · 4 filings
  • Sep 11, 2025 · D · $96,130,465 sold of $141,066,486 · 28 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 22, 2022 · D · $4,000,000 sold of $4,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 9, 2022 · D · $2,000,000 sold of $2,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 18, 2019 · D/A · $42,514,946 sold of $43,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $96.1M from 28 investors (68% of the $141.1M target) as of the latest filing. Seth is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AB
Biotechnology

Aulos Bioscience, Inc.

Larkspur, CA · Aug 10, 2023
  • Aug 10, 2023 · D · $5,000,000 sold of $20,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $15M from 1 investor (75% of the $20M target) as of the latest filing. Seth is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AT
Biotechnology

Aethon Therapeutics, Inc.

New York, NY · Dec 22, 2022
  • Dec 22, 2022 · D · $6,000,000 sold of $30,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $6M from 2 investors (20% of the $30M target) as of the latest filing. Seth is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RB
Biotechnology

Replicate Bioscience, Inc.

San Diego, CA · Feb 16, 2021 → Mar 9, 2022 · 2 filings
  • Mar 9, 2022 · D/A · $20,000,000 sold of $53,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 16, 2021 · D · $6,000,000 sold of $40,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $20M from 1 investor (38% of the $53M target) as of the latest filing. Seth is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

MT
Biotechnology

Marlinspike Therapeutics, Inc.

Cambridge, MA · Feb 28, 2022
  • Feb 28, 2022 · D · $3,500,000 sold of $65,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $3.5M from 1 investor (5% of the $65M target) as of the latest filing. Seth is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

DA
Biotechnology

Deep Apple Therapeutics, Inc.

New York, NY · Dec 22, 2021
  • Dec 22, 2021 · D · $5,000,000 sold of $52,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $5M from 1 investor (10% of the $52M target) as of the latest filing. Seth is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

GM
Biotechnology · group: Galvanize Therapeutics

Galaxy Medical, Inc.

San Carlos, CA · Apr 1, 2020 → Nov 10, 2021 · 4 filings
  • Nov 10, 2021 · D · $750,000 sold of $750,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 4, 2021 · D · $1,250,000 sold of $1,250,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 29, 2020 · D/A · $8,000,000 sold of $18,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 1, 2020 · D · $200,000 sold of $5,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $8M from 1 investor (100% of the $750K target) as of the latest filing. Seth is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RQ
Biotechnology

Red Queen Therapeutics, Inc.

Cambridge, MA · Nov 2, 2021
  • Nov 2, 2021 · D · $5,000,000 sold of $55,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $5M from 1 investor (9% of the $55M target) as of the latest filing. Seth is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

EB
Biotechnology

Evercrisp Biosciences, Inc.

New York, NY · Aug 25, 2021
  • Aug 25, 2021 · D · $3,500,000 sold of $75,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $3.5M from 1 investor (5% of the $75M target) as of the latest filing. Seth is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

IT
Biotechnology

Initial Therapeutics, Inc.

New York, NY · Jul 16, 2020 → Feb 4, 2021 · 2 filings
  • Feb 4, 2021 · D/A · $3,800,000 sold of $75,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 16, 2020 · D · $1,000,000 sold of $75,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $3.8M from 1 investor (5% of the $75M target) as of the latest filing. Seth is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

NS
Biotechnology

Nine Square Therapeutics Corp

New York, NY · Jul 1, 2020 → Feb 3, 2021 · 2 filings
  • Feb 3, 2021 · D/A · $4,200,000 sold of $50,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 1, 2020 · D · $1,000,000 sold of $50,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $4.2M from 1 investor (8% of the $50M target) as of the latest filing. Seth is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AP
Pharmaceuticals

Apertor Pharmaceuticals, Inc.

New York, NY · Nov 17, 2020
  • Nov 17, 2020 · D · $3,000,000 sold of $50,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $3M from 1 investor (6% of the $50M target) as of the latest filing. Seth is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

GT
Biotechnology · group: Galvanize Therapeutics

Galvanize Therapeutics, Inc.

San Carlos, CA · Apr 1, 2020 → Oct 29, 2020 · 2 filings
  • Oct 29, 2020 · D/A · $6,100,863 sold of $16,100,863 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 1, 2020 · D · $200,000 sold of $2,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $6.1M from 1 investor (38% of the $16.1M target) as of the latest filing. Seth is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

GT
Biotechnology

Galavant Therapeutics, Inc.

Menlo Park, CA · Apr 1, 2020
  • Apr 1, 2020 · D · $100,000 sold of $100,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $100K from 1 investor (100% of the $100K target) as of the latest filing. Seth is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

TM
Biotechnology

Tusker Medical, Inc.

Menlo Park, CA · Jul 11, 2019 → Oct 15, 2019 · 2 filings
  • Oct 15, 2019 · D · $2,000,000 sold of $5,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 11, 2019 · D · $4,000,000 sold of $4,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $17.3M from 2 investors (100% of the $5M target) as of the latest filing. Seth is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

ST
Biotechnology

Stoke Therapeutics, Inc.

Bedford, MA · Nov 2, 2018
  • Nov 2, 2018 · D · $90,000,000 sold of $90,000,000 · 14 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $90M from 14 investors (100% of the $90M target) as of the latest filing. Seth is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

CF
Other Technology

Cure Forward Corp.

Boston, MA · Nov 14, 2014 → May 18, 2017 · 6 filings
  • May 18, 2017 · D/A · $4,499,997 sold of $4,499,997 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 20, 2016 · D · $3,999,997 sold of $3,999,997 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 29, 2016 · D · $4,325,056 sold of $6,125,056 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 22, 2015 · D · $3,500,000 sold of $15,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 22, 2015 · D/A · $4,000,000 sold of $4,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 14, 2014 · D · $500,000 sold of $2,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $4.5M from 1 investor (100% of the $4.5M target) as of the latest filing. Seth is listed as director on 6 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Technology / 506(b) (17,390 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AT
Biotechnology

AILERON THERAPEUTICS INC

Waltham, MA · Jun 12, 2009 → Jan 6, 2017 · 4 filings
  • Jan 6, 2017 · D · $30,112,894 sold of $40,000,000 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 29, 2014 · D · $19,799,999 sold of $32,999,999 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 19, 2013 · D · $15,000,003 sold of $30,000,000 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 12, 2009 · D · $28,105,002 sold of $40,150,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $30.1M from 15 investors (75% of the $40M target) as of the latest filing. Seth is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

S
Biotechnology

Syntimmune, Inc.

New York, NY · Oct 24, 2014
  • Oct 24, 2014 · D · $8,000,001 sold of $26,000,002 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $18M from 5 investors (69% of the $26M target) as of the latest filing. Seth is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

EP
Biotechnology

Eledon Pharmaceuticals, Inc.

Irvine, CA · May 6, 2009 → May 15, 2013 · 3 filings
  • May 15, 2013 · D · $19,999,993 sold of $35,499,985 · 19 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 20, 2011 · D · $1,892,794 sold of $22,999,986 · 6 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • May 6, 2009 · D · $10,000,000 sold of $22,000,000 · 10 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $108.1M from 38 investors (100% of the $35.5M target) as of the latest filing. Seth is listed as director, executive officer on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

HI
Other Health Care

HeartWare International, Inc.

Framingham, MA · Aug 14, 2009 → Oct 5, 2009 · 2 filings
  • Oct 5, 2009 · D · $220,000 sold of $220,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 14, 2009 · D · $55,000,000 sold of $55,000,000 · 30 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $55M from 30 investors (100% of the $220K target) as of the latest filing. Seth is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

GP
Biotechnology

Gloucester Pharmaceuticals Inc

Cambridge, MA · Apr 10, 2009 → Aug 21, 2009 · 6 filings
  • Aug 21, 2009 · D · $20,324,914 sold of $28,881,642 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 12, 2009 · D · $500,000 sold of $500,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 17, 2009 · D · $500,000 sold of $500,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 10, 2009 · D · $1,500,000 sold of $1,500,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 6, 2009 · D · $1,700,000 sold of $1,700,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 10, 2009 · D · $1,500,000 sold of $1,500,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $20.3M from 9 investors (70% of the $28.9M target) as of the latest filing. Seth is listed as director on 6 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other pages with the same name (2)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

  • Seth L. Harrison — PA, 1 issuer, Aug 15, 2019 → Aug 15, 2019 · no shared issuer
  • Seth L. Harrison — NY, NJ, 1 issuer, Jun 28, 2012 → Jun 28, 2012 · no shared issuer

People around Seth 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

JW
No photo found yet (own website and image search run after this page is viewed)
Person

Jonathan Waldstreicher

Executive Officer, Director · 11 shared filings (4 issuers)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

JY
No photo found yet (own website and image search run after this page is viewed)
Person

Joseph A. Yanchik III

Executive Officer, Director · 10 shared filings (4 issuers) · also on 1 other issuer

Joseph A. Yanchik III is on 5 issuers in total — a repeat sponsor. Their page lists every one.

ME
No photo found yet (own website and image search run after this page is viewed)
Person

Michael Ehlers

Director, Executive Officer · 8 shared filings (5 issuers)

Michael Ehlers is on 5 issuers in total — a repeat sponsor. Their page lists every one.

SL
No photo found yet (own website and image search run after this page is viewed)
Person

Spiros Liras

Executive Officer, Director · 8 shared filings (6 issuers)

Spiros Liras is on 6 issuers in total — a repeat sponsor. Their page lists every one.

AC
No photo found yet (own website and image search run after this page is viewed)
Person

Alan Colowick

Executive Officer, Director · 6 shared filings (1 issuer) · also on 9 other issuers

Alan Colowick is on 10 issuers in total — a repeat sponsor. Their page lists every one.

RA
No photo found yet (own website and image search run after this page is viewed)
Person

Reinhard J. Ambros

Director · 6 shared filings (2 issuers) · also on 2 other issuers

Listed on the same filings as Seth Harrison. Their page shows their other deals.

JN
No photo found yet (own website and image search run after this page is viewed)
Person

Jean C. Nichols

Executive Officer · 6 shared filings (1 issuer)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

NV
No photo found yet (own website and image search run after this page is viewed)
Person

Nicholas Vrolijk

Executive Officer · 6 shared filings (1 issuer)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

JM
No photo found yet (own website and image search run after this page is viewed)
Person

Jay Moorin

Director · 6 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Seth Harrison. Their page shows their other deals.

MV
No photo found yet (own website and image search run after this page is viewed)
Person

Martin Vogelbaum

Director · 6 shared filings (1 issuer) · also on 8 other issuers

Martin Vogelbaum is on 9 issuers in total — a repeat sponsor. Their page lists every one.

DH
No photo found yet (own website and image search run after this page is viewed)
Person

Donald J. Hayden

Executive Officer, Director · 6 shared filings (1 issuer) · also on 4 other issuers

Donald J. Hayden is on 5 issuers in total — a repeat sponsor. Their page lists every one.

DS
No photo found yet (own website and image search run after this page is viewed)
Person

David Schnell

Director · 6 shared filings (1 issuer) · also on 8 other issuers

David Schnell is on 9 issuers in total — a repeat sponsor. Their page lists every one.

AK
No photo found yet (own website and image search run after this page is viewed)
Person

Aaron Kantoff

Director · 6 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Seth Harrison. Their page shows their other deals.

CM
No photo found yet (own website and image search run after this page is viewed)
Person

Campbell Murray

Director · 4 shared filings (2 issuers) · also on 12 other issuers

Campbell Murray is on 14 issuers in total — a repeat sponsor. Their page lists every one.

TB
No photo found yet (own website and image search run after this page is viewed)
Person

Timothy J. Barberich

Director · 4 shared filings (2 issuers) · also on 9 other issuers

Timothy J. Barberich is on 11 issuers in total — a repeat sponsor. Their page lists every one.

MN
No photo found yet (own website and image search run after this page is viewed)
Person

Martin Naley

Executive Officer, Director · 4 shared filings (1 issuer)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

RC
No photo found yet (own website and image search run after this page is viewed)
Person

Rajesh Chopra

Director, Executive Officer · 4 shared filings (3 issuers)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

EP
No photo found yet (own website and image search run after this page is viewed)
Person

Enrico Petrillo

Director · 3 shared filings (1 issuer) · also on 7 other issuers

Enrico Petrillo is on 8 issuers in total — a repeat sponsor. Their page lists every one.

DK
No photo found yet (own website and image search run after this page is viewed)
Person

David Kessler

Director · 3 shared filings (1 issuer)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

SK
No photo found yet (own website and image search run after this page is viewed)
Person

Scott Kapnick

Director · 3 shared filings (1 issuer)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

JM
No photo found yet (own website and image search run after this page is viewed)
Person

John H. McArthur

Director · 3 shared filings (1 issuer)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

FI
No photo found yet (own website and image search run after this page is viewed)
Person

Frank Ingari

Executive Officer, Director · 3 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Seth Harrison. Their page shows their other deals.

LF
No photo found yet (own website and image search run after this page is viewed)
Person

Lauren Farrell

Executive Officer · 3 shared filings (1 issuer)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

PB
No photo found yet (own website and image search run after this page is viewed)
Person

Preston Brice

Director · 3 shared filings (1 issuer)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

DM
No photo found yet (own website and image search run after this page is viewed)
Person

David McIntyre

Executive Officer, Director · 3 shared filings (2 issuers) · also on 2 other issuers

Listed on the same filings as Seth Harrison. Their page shows their other deals.

SH
No photo found yet (own website and image search run after this page is viewed)
Person

Steve Hau

Executive Officer · 3 shared filings (1 issuer)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

SP
No photo found yet (own website and image search run after this page is viewed)
Person

Stephanie Papes

Director · 3 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Seth Harrison. Their page shows their other deals.

DG
No photo found yet (own website and image search run after this page is viewed)
Person

Doug Godshall

Director, Executive Officer · 3 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Seth Harrison. Their page shows their other deals.

PJ
No photo found yet (own website and image search run after this page is viewed)
Person

Paul Da Silva Jardine

Director, Executive Officer · 3 shared filings (3 issuers)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

BG
No photo found yet (own website and image search run after this page is viewed)
Person

Brian M. Gallagher, Jr.

Director · 3 shared filings (1 issuer)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

AA
No photo found yet (own website and image search run after this page is viewed)
Person

Amir Abolfathi

Executive Officer, Director · 2 shared filings (1 issuer) · also on 8 other issuers

Amir Abolfathi is on 9 issuers in total — a repeat sponsor. Their page lists every one.

RT
No photo found yet (own website and image search run after this page is viewed)
Person

Robert Thomas

Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Seth Harrison. Their page shows their other deals.

DG
No photo found yet (own website and image search run after this page is viewed)
Person

Douglas Godshall

Director, Executive Officer · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Seth Harrison. Their page shows their other deals.

JL
No photo found yet (own website and image search run after this page is viewed)
Person

Jeffrey A. LaRose

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

AS
No photo found yet (own website and image search run after this page is viewed)
Person

Armen Shanafelt

Director · 2 shared filings (1 issuer)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

MJ
No photo found yet (own website and image search run after this page is viewed)
Person

Matthew Jacobson

Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Seth Harrison. Their page shows their other deals.

JW
No photo found yet (own website and image search run after this page is viewed)
Person

Jon Waldstreicher

Director · 2 shared filings (1 issuer)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

JC
No photo found yet (own website and image search run after this page is viewed)
Person

James H. Doudna Cate

Director · 2 shared filings (1 issuer)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

NW
No photo found yet (own website and image search run after this page is viewed)
Person

Nathaniel Wang

Executive Officer, Director · 2 shared filings (1 issuer)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

AB
No photo found yet (own website and image search run after this page is viewed)
Person

Anna Batarina

Director · 2 shared filings (2 issuers)

Listed on the same filings as Seth Harrison. Their page shows their other deals.

The team behind the deals

GT
Sponsor group

Galvanize Therapeutics

3 issuers · 11 filings · $103M reported sold · 2019–2025

One team, 3 deal companies. Seth Harrison is listed on 3 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Seth Harrison.

Same business address

51 other issuers file from the same address (first 50 shown)

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Business registration (state registry / Secretary of State)

Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).

Adviser registration (Form ADV)

None of the 22 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Seth Harrison by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 22 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Seth Harrison is listed on: none on file. No website or social profile named in Stoke Therapeutics, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #245,151 of 374,652 in line (1,386 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Bedford, MA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗Massachusetts MassCourts ↗New York WebCivil Supreme ↗California — find the county court ↗Los Angeles Superior Court case search ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

Massachusetts Secretary of State business search ↗New York Secretary of State business search ↗California Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Seth Harrison appears on a new Form D, or when a court case or SEC action is matched to them. See plans →